These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 21659624

  • 1. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J.
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z, Wheeler JJ, Townsend R, Gao Y, Kshirsagar S, Keirns JJ.
    J Pharmacokinet Pharmacodyn; 2011 Oct 01; 38(5):541-62. PubMed ID: 21786177
    [Abstract] [Full Text] [Related]

  • 5. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Expert Opin Investig Drugs; 2009 Dec 01; 18(12):1929-37. PubMed ID: 19938903
    [Abstract] [Full Text] [Related]

  • 6. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I.
    Med Monatsschr Pharm; 2011 May 01; 34(5):154-8. PubMed ID: 21644373
    [Abstract] [Full Text] [Related]

  • 7. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 01; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 8. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May 01; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct 01; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 10. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
    Mao ZL, Alak A, Wheeler JJ, Keirns J.
    Drug Metab Lett; 2011 Apr 01; 5(2):114-25. PubMed ID: 21457140
    [Abstract] [Full Text] [Related]

  • 11. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 01; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 12. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE.
    Curr Opin Investig Drugs; 2010 Sep 01; 11(9):1048-58. PubMed ID: 20730700
    [Abstract] [Full Text] [Related]

  • 13. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN.
    Int J Cardiol; 2013 Jun 05; 166(1):147-51. PubMed ID: 22108512
    [Abstract] [Full Text] [Related]

  • 14. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May 05; 21(127):119-22. PubMed ID: 22827000
    [Abstract] [Full Text] [Related]

  • 15. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007 May 05; 8(4):259-65. PubMed ID: 17596113
    [Abstract] [Full Text] [Related]

  • 16. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
    Tian D, Frishman WH.
    Cardiol Rev; 2011 May 05; 19(1):41-4. PubMed ID: 21135602
    [Abstract] [Full Text] [Related]

  • 17. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA, Lau YC, Lip GY.
    Expert Opin Pharmacother; 2014 Apr 05; 15(6):865-72. PubMed ID: 24617913
    [Abstract] [Full Text] [Related]

  • 18. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E, Atrial Arrhythmia Conversion Trial Investigators.
    Circ Arrhythm Electrophysiol; 2009 Dec 05; 2(6):652-9. PubMed ID: 19948506
    [Abstract] [Full Text] [Related]

  • 19. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN, Eschenhagen T.
    Dtsch Med Wochenschr; 2010 May 05; 135(19):971-6. PubMed ID: 20446233
    [Abstract] [Full Text] [Related]

  • 20. [Vernakalant for the conversion of atrial fibrillation of recent onset].
    Seoane L, Baranchuk A, Conde D.
    Medicina (B Aires); 2015 May 05; 75(4):239-44. PubMed ID: 26339882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.